mk-8189
Small moleculeexperimental
Clinical trial activity
12 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2014 (NCT02181803)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 10AINHIBITOR
PDE10A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc([C@H]2C[C@@H]2COc2cc(NCc3nnc(C)s3)nc(C)n2)nc1- Mol. weight
- 382.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314924 ↗
Also known as
- mk-8189
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06273774 | Phase 1 | Apr 8, 2024 | Merck |
| NCT05953740 | Phase 1 | Sep 15, 2023 | Merck |
| NCT05893862 | Phase 1 | Jun 26, 2023 | Merck |
| NCT05406440 | Phase 1 | Jul 12, 2022 | Merck |
| NCT05227118 | Phase 1 | Jul 1, 2022 | Merck |
| NCT06626464 | Phase 1 | May 13, 2022 | Merck |
| NCT04676425 | Phase 1 | Feb 2, 2021 | Merck |
| NCT04624243 | Phase 2 | Dec 15, 2020 | Merck |
| NCT04506905 | Phase 1 | Aug 26, 2020 | Merck |
| NCT03565068 | Phase 1 | Jun 19, 2018 | Merck |
| NCT03055338 | Phase 2 | Mar 8, 2017 | Merck |
| NCT02181803 | Phase 1 | Aug 1, 2014 | Merck |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 12 | 12 | 2 | 2014 |
1 organizations
Page 1 / 1